Biotech Values

[DewDiligence]

FDA approves LLY’s Retevmo (selpercatinib/LOXO-292) for certain RET-mutation/fusion cancers:

https://www.prnewswire.com/news-releases/fda-approves-first-therapy-for-patients-with-lung-and-thyroid-cancers-with-a-certain-genetic-mutation-or-fusion-301056045.html

Retevmo was developed by LOXO, acquired by LLY for $8B in Jan 2019 (#msg-145917745).